Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage ...
Phase 1b study of DNL151 includes Parkinson’s disease patients with and without a genetic LRRK2 mutation Either DNL151 or DNL201 anticipated to be selected for potential registrational clinical trials in 2020 The Engage Parkinson’s website provides …